special drug delivery systems
TRANSCRIPT
-
7/29/2019 Special Drug Delivery Systems
1/60
28/12/2012
-
7/29/2019 Special Drug Delivery Systems
2/60
Definition
Types
Mechanism of drug delivery
Applications
Merits
Demerits
Future prospects
-
7/29/2019 Special Drug Delivery Systems
3/60
SPECIAL DRUG DELIVERY SYSTEM:
These are various types of drug deliverysystems which incorporate drugs in a dosage form
that releases the medication at a predeterminedsite and rate, over the extended period of timefrom a single application.
R.S.SATOSKAR, 21st ed.
-
7/29/2019 Special Drug Delivery Systems
4/60
TYPES OF SPECIAL DRUG DELIVERY
SYSTEM1. Devices for slow, prolonged release of a drug for topical
action- ocusert, progestasert, transdermal patches andiontophoresis.
2. Implants and drug-eluting stents.
3. A device for rapid delivery of anti-convulsantLorazepam to the CNS.
4. Prodrugs.
5. Targeted drug delivery systems.
6. Computerized miniature pumps.
-
7/29/2019 Special Drug Delivery Systems
5/60
DEVICES FOR SLOW, PROLONGED
RELEASE OF A DRUG FOR TOPICALAPPLICATION
OCUSERTS: thin elliptical microunits, contain the drug ina reservoir from which the drug is slowly released through amembrane by diffusion at a steady rate.
- Pilocarpine Glaucoma.
- round the clock for 7days.
-
7/29/2019 Special Drug Delivery Systems
6/60
Pilo-20 and Pilo-40: release 20g and 40g of
pilocarpine per hour respectively for 7days.
Advantages:
Rapid absorption.
Ease of administration.
Good local tolerance.
Avoids the need for repeated administration
of eye drops.
-
7/29/2019 Special Drug Delivery Systems
7/60
-
7/29/2019 Special Drug Delivery Systems
8/60
Recent trends:
Polymer solution
Phase transition system
Micro adhesive/ biodhesive dosage forms
Collagen shields
Pendolatices
Ocular penetration enhancers
-
7/29/2019 Special Drug Delivery Systems
9/60
PROGESTASERT:
An intrauterine contraceptive device
1st hormonal uterine device 1976
Controlled release of minute quantities of progesterone
(38mg) within the uterus for a year
-
7/29/2019 Special Drug Delivery Systems
10/60
-
7/29/2019 Special Drug Delivery Systems
11/60
Uses:
Contraception.
Menorrhagia, dysmenorrhoea.
Contraindications:
Weight gain
Pregnancy, ectopic pregnancy.
Immediately after septic abortion, Postpartum puerperal
sepsis.
PID
Endometrial cancer, cervical cancer.
-
7/29/2019 Special Drug Delivery Systems
12/60
Advantages: Prolonged action (1 yr)
Adverse effects and complications:
Expulsion (4%) [ Nulliparous- 3%]
Failure rate of2%.
Bleeding, anemia
PID, Uterine perforation.
Endometriosis, ectopic pregnancy.Withdrawn from the market since 2001.
-
7/29/2019 Special Drug Delivery Systems
13/60
Mirena (1990-present):1st marketed in Finland in 1990.
approved by U.S. FDA in 2000.
20 g of levonorgestrel per day.
uses - +endometriosis, DUB.
May be used for 5 yrs.
Products in development:Femilis:a lower-dose (14g levonorgestrel per day) T-frame
IUS, developed by the Belgian companyContrel.
FibroPlant-LNG: a frameless IUS, initially releases 14g oflevonorgestrel per day, and may be used for a period of3 yrs.
-
7/29/2019 Special Drug Delivery Systems
14/60
TRANSDERMAL DRUG DELIVERY SYSTEM:
These are devices in the form of adhesive patches ofvarious shapes and sizes (15-20 cm) which deliver thecontained drug at a constant rate into systemic circulation
via the stratum corneum.
-
7/29/2019 Special Drug Delivery Systems
15/60
Designed to last for 1-7 days.
The sites of application: chest
abdomen
upper arm lower back
buttock
mastoid region (efficient)
GTN, fentanyl, nicotine and estradiol - India.
Isosorbide dinitrate, hyoscine and clonidine.
-
7/29/2019 Special Drug Delivery Systems
16/60
The potential advantages:
Minimize inter individual variations (drug is subjected tolittle hepatic first pass metabolism).
Provide smooth plasma concentration of drug without
fluctuations.
Maintains constant blood levels for of drug longer period
of time.
Decreases gastrointestinal effect that occur due to local
contact with gastric mucosa.
More convenient - improved compliance.
-
7/29/2019 Special Drug Delivery Systems
17/60
Disadvantages: Local irritation and erythema, generally mild.
Discontinuation - 2-7% cases.
-
7/29/2019 Special Drug Delivery Systems
18/60
Transderm Scop:
Transdermal preparation of scopalamine.
Post auricular area
1.5 mg/2.5cm2
0.5mg/24hr over a period of75hrs.
Transdermal local anaesthetic delivery system: successfully introduced into the clinical practice forproviding topical analgesia.
-
7/29/2019 Special Drug Delivery Systems
19/60
Future aspects:
To extend the duration of local anaesthetic action.
Novel delivery system in development-
Polymers
Liposomes
Suspensions.
A mutlivesicular liposomal formation of bupivacaine
(Depo Bupivacaine) is in the advanced stages of clinicaldevelopment.
- Action lasting up to 72 hrs.
-
7/29/2019 Special Drug Delivery Systems
20/60
IONTOPHORESIS [Electromotive Drug Administration
(EMDA)]: is a technique using a small electric charge to deliver amedicine or other chemical through the skin.
basically an injection without the needle.
unlike transdermal patches, this method relies on activetransportation within an electric field.
galvanic current
-
7/29/2019 Special Drug Delivery Systems
21/60
Galvanic current
Eg. Salicylates
-
7/29/2019 Special Drug Delivery Systems
22/60
-
7/29/2019 Special Drug Delivery Systems
23/60
Uses:
anti-inflammatory medications (physiotherapy) plantar fasciitis, bursitis and some typesof hyperhidrosis
Adverse effect:mild skin irritation transient.
Future aspects:- local anaesthetics
- ocular iontophoresis
-
7/29/2019 Special Drug Delivery Systems
24/60
IMPLANTS AND STENT
SUBCUTANEOUS IMPLANTS:
- Drug is deposited in loose subcutaneous tissue, richlysupplied by nerves but is less vascular
- Repository (depot) preparations can be injected forprolonged action
Pellet implantation:
- Drug in the form of solid pellet is introduced with atrochar and cannula.
- Provides sustained release-over weeks and monthsEg: testosterone.
-
7/29/2019 Special Drug Delivery Systems
25/60
Sialistic (Nonbiodegradable) and biodegradable
implants:- Crystalline drug is packed in tubules or capsules made of
suitable materials and implanted under skin.
- release drug over months
Norplant: nonbiodegradable hormonal contraceptive
- set of 6 capsules each containing 36 mg levonorgestrel(216mg)
- up to 5yrs
-
7/29/2019 Special Drug Delivery Systems
26/60
Dermojet:
- a high velocity jet of drug solution is projected from amicrofine orifice using a gun like implement.
- needle is not used- painless
- suited for mass inoculations
- insulin
-
7/29/2019 Special Drug Delivery Systems
27/60
DRUGELUTING STENTS:
Peripheral or coronary stent (a scaffold) placed intonarrowed, diseased peripheral or coronary arteries that
slowly releases a drug to block cell proliferation.
These stents consist of a metallic stent backbone coveredby a polymer, containing a drug (SIROLIMUS OR
PACLITAXEL).
The first successful trials were of sirolimus - eluting stents
Drug is gradually released- 14-30 days
-
7/29/2019 Special Drug Delivery Systems
28/60
Expensive.
Indications:- coronary stenting
- improve the diameter of the coronary artery lumen
Risks:
- new clot/thrombosis formation with stents
- Stent occlusion because of thrombosis may occur
during the procedure, in the following days, or later.
-
7/29/2019 Special Drug Delivery Systems
29/60
-
7/29/2019 Special Drug Delivery Systems
30/60
A DEVICE FOR RAPID DELIVERY OF
ANTICONVULSANT LORAZEPAM TO
THE CNS
In Status epilepticus, Lorazepam has been
administered by squirting it intranasally using anatomizingpump.
- reaches the brain rapidly along the perineural pathwaysof olfactory and trigeminal nerves
- bypasses the BBB.
- acts within minutes.
-
7/29/2019 Special Drug Delivery Systems
31/60
PRODRUGS
It is an inactive form of drug which gets metabolized in
the body to an active drug, or one or more active metabolite.
Overcome the pharmacokinetic disadvantages of the
useful drug.
More stable
Better bioavailability
Less side and toxicity
-
7/29/2019 Special Drug Delivery Systems
32/60
Dopamine Levodopa (BBB - Parkinsonism)
Enalapril Enalaprilat
Esters of antipsychotic phenothiazines likefluphenazine (longer duration of action)
Methenamine prodrug for formaldehyde. It isconverted to formaldehyde and ammonia at acidic urinaryPH (Site specific delivery of drugs)
Altering polarity of ampicillin by esterifying ampicillin
to form talampicillin - improves bioavailability ofampicillin.
-
7/29/2019 Special Drug Delivery Systems
33/60
TARGETED DRUG DELIVERY SYSTEM(SMART DRUG DELIVERY)
It is the one, which delivers the drug only to its site of
action and not to the non-target organs or tissues.
produce maximum stability activity and bioavailability.
the goal is to prolong, localize, target and have a protecteddrug interaction with the diseased tissue.
-
7/29/2019 Special Drug Delivery Systems
34/60
The advantages:
reduction in the frequency of the dosages taken by thepatient
having a more uniform effect of the drug
reduction of drug side effects
reduced fluctuation in circulating drug levels.
Disadvantages:
High cost.
Reduced ability to adjust the dosages.
-
7/29/2019 Special Drug Delivery Systems
35/60
Two kinds of T.D.D-
1. Active T.D.D- such as some antibody medications.2. Passive T.D.D- enhanced permeability and retention
effect.
Types of Targeted drug delivery system:1. Monoclonal antibodies (MAbs)
2. Liposomes
3. Nanoparticles (Nanopharmacology)
4. Polymeric micelles
5. Dendimers
-
7/29/2019 Special Drug Delivery Systems
36/60
MONOCLONAL ANTIBODIES (MAbs):These are antibodies produced by a single clone of
lymphocytes or plasma cells and directed against a singleantigenic determinant (epitope).
Georges Kohler and Cesar Milstein in 1975.
Noble Prize for Medicine in 1984 - hybridomatechnology.
-
7/29/2019 Special Drug Delivery Systems
37/60
Conventional production of MAbs:
The hybridoma technology:B lymphocytes from spleen of immunized mice are fused
with the murine myeloma cells.
Classified into four fields (depending on cell culturemethods):
1. Robottle cell culture process.
2. Membrane binded cell culture process.
3. Microcarrier cell culture process.
4. Suspended cell culture process.
-
7/29/2019 Special Drug Delivery Systems
38/60
-
7/29/2019 Special Drug Delivery Systems
39/60
-
7/29/2019 Special Drug Delivery Systems
40/60
-
7/29/2019 Special Drug Delivery Systems
41/60
The types/sources of MAbs:
1. Murine (rodents) MAbs: shorter life,- induce a human antimouse antibody allergicreactions.
2. Chimeric MAbs: murine MAbs partly humanized by
genetic manipulation (part human part mouseantibody)
3. Humanized MAbs: obtained by recombinant DNAtechnology or by grafting of complimentarity
determining regions (CDRs) of murine MAbs onhuman Ig framework- least antigenic
-
7/29/2019 Special Drug Delivery Systems
42/60
Nomenclature of MAbs:Prefix + Target subsystem + Origin subsystem + Suffix.
Suffix- mab.
Origin- depending on sourcezu- human (zumab), xi- chimeric (ximab),
o- murine (omab). Target- specific letters
vi- virus (Palivizumab),ci- circulation (Abciximab),
tu- tumour (Trastuzumab),If no such prefix, then the MAb is generally animmunomodulator (Infliximab).
Prefix- different for each Mab.
-
7/29/2019 Special Drug Delivery Systems
43/60
Prefix Target subsystem Source subsystem
Old New Meaning Meaning
Variable
vi (r)ba (c)li (m)fu (ng)ne (r)ki (n)mu (l)o (s)
v (i)b (a)l (i)f (u)n (e)k (i)-s (o)
ViralBacterialLower immunityFungalNervous systemInterleukin as targetMusculoskeletalBone
uoaixizuaxoxizu
HumanMouseRatPrimateChimericHumanizedRat mouse hybridChimeric humanizedhybrid
co (l)me (l)
ma (r)go (t)go (v)pr (o)tu (m)
-t (u)
Colonic tumorMelanoma
Mammary tumorTesticular tumorOvarian tumorProstate tumorMiscellaneous tumor
-
7/29/2019 Special Drug Delivery Systems
44/60
Mab Target Indication
Abciximab Alemtuzumab Bevacizumab Cetuximab Daclizumab
Gemtuzumab Palivizumab Rituximab Trastuzumab
Gp II/IIIaCD 52
VEGFEGFRIL-2R
CD 33Fusion proteinCD 20her- 2/neu
AntiplateletB cell CLLColorectal Ca.Colorectal Ca.TR
AMLRSV infectionB cell NHLBreast cancer
VEGF- vascular endothelial growth factor. EGFR- epithelial growth factor receptor. TR- transplant rejection NHL- non-Hodgkins lymphoma. AML- acute myeloid leukemia. RSV respiratory syncytial virus.
-
7/29/2019 Special Drug Delivery Systems
45/60
Application of MAbs:
Diagnostic tests- Western blot test, immuno dot blottest, immunohistochemistry, immunofluorescence test,biosensors, microarrays.
Therapeutic treatment
Clinical applications- purification of drugsimaging the target
Autoimmune diseases- rheumatoid arthritis
(infliximab), Crohns disease, ulcerative colitis, acuterejection of kidney transplants and asthma
-
7/29/2019 Special Drug Delivery Systems
46/60
Three mechanisms could be responsible for the cancertreatment:
A. MAbs act directly when binding to a cancer specificantigen and induce immunological response tocancer cells. Such as inducing cancer cell apoptosis,
inhibiting growth or interfering with a key function.B. MAbs was modified for delivery of a toxin,
radioisotope, cytokine or other active conjugates.
C. it is also possible to design bispecific antibodies that
can bind with their Fab regions both to target antigenand to a conjugate or effector cell
-
7/29/2019 Special Drug Delivery Systems
47/60
Adverse reactions:
Hypersensitivity reactions (rare)
Suppression of physiologic function- may occur
Activation of inflammatory cells
Increased risk of infection and cancer
-
7/29/2019 Special Drug Delivery Systems
48/60
LIPOSOMES:
These are concentric, spherical shells of phospholipidsin a watery medium, into which drugs are incorporated.
Produced by sonificaton of aqueous suspension ofphospholipids.
Administered by I.V route.
Most common vehicle currently used for T.D.D
Non toxic, non hemolytic and non immunogenic- evenon repeated injections.
-
7/29/2019 Special Drug Delivery Systems
49/60
-
7/29/2019 Special Drug Delivery Systems
50/60
Drugs administered via liposomes are:
- anti cancer drugs (daunorubicin and doxorubicin).
- anti fungal drugs (amphotericin B)- less nephrotoxic andbetter tolerated.
- antibiotic like gentamicin.
Disadvantage: Biodegradable - immediate uptake andclearance by RE system.
- overcome by adding poly ethylene glycol (PEG).
-
7/29/2019 Special Drug Delivery Systems
51/60
NANOPHARMACOLOGY:
The application of nanotechnology to the developmentand/or discovery of methods to deliver drugs.
a nanodrug can be a vector (nanovector) designed todeliver a pharmacological agent (drug).
Nanos = dwarf (Greek word), patuljak (Croatian)
1 nm = 10-9 m
Term nanotechnology was introduced by NorioTaniguchi, 1974.
http://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdf -
7/29/2019 Special Drug Delivery Systems
52/60
Designed to allow controlled (sustained) drug releasefrom matrix
Advantages: high stability, high carrier capacity
can solubilize water insoluble compounds
feasibility of variableroutes of administration, includingoral application and inhalation.
can reduce toxicity of anticancer agents
Passive targeting: enhanced permeability and retentioneffect
http://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2.pdf -
7/29/2019 Special Drug Delivery Systems
53/60
Applications of Nanopharmacology:
Anticancer therapy- paclitaxel, 5- fluorouracil,doxorubicin
Drug and tumor targeting, imaging.
Alzheimers disease
Potentialfor treatment of tuberculosis (TB)
FUTURE of drug delivery
http://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2%20(2).pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2%20(2).pdfhttp://localhost/var/www/apps/conversion/tmp/scratch_3/PL-4%201200%20D.%20Maysinger2%20(2).pdf -
7/29/2019 Special Drug Delivery Systems
54/60
Type of Nanoparticles Material used Application
1. Polymeric
nanoparticles
Biodegradable polymers Controlled and T.D.D
2. Quantum dots CdSe-CdS core-shell Targeting, imaging agent
3. Nanopores Aerogel, produced by sol-gel chemistry
Controlled release drugcarriers
4. Nanowires or carbon
nanotubes
Metals, semiconductors or
carbon
Gene and DNA delivery
5. Nanoshells coatedwith gold
Dielectric (typically goldsulfide or silica) core or ametal (gold) shell
Tumor targeting
6. Liposomes Phospholipid vesicles Controlled and T.D.D
7. Ceramicnanoparticles
Silica, alumina, titania Drug targeting,Bio-molecules delivery
8. Polymeric micelles Amphiphilic blockcopolymers
Systemic and controlleddelivery of water insoluble drugs
-
7/29/2019 Special Drug Delivery Systems
55/60
MICELLES: prepared from certain amphiphilic co-
polymers consisting of both hydrophilic and hydrophobicmonomer units.
can be used to carry drugs that have poor solubility
Limitations- offers little in terms of size control or functionmalleability.
DENDRIMERS: These are also polymer based deliveryvehicles.
have a core that branches out in regular intervals to forma small, spherical and very dense nanocarrier.
-
7/29/2019 Special Drug Delivery Systems
56/60
Application of T.D.D:
Cancer treatment
Cardiovascular diseases
Diabetes mellitus
Infectious diseases
Inflammatory diseases
Transplant rejections
-
7/29/2019 Special Drug Delivery Systems
57/60
COMPUTERISED MINIATURE PUMPS:
Programmed to release drugs at a definite rate, eithercontinuously as in case of insulin or intermittently in pulsesas in case of GnRH.
May also be provided with glucose sensor devices which
trigger the desired dose of insulin as per body's demand.
Insulin pumps: Portable infusion devices connected to asubcutaneously placed cannula
- provides continuous s.c insulin infusion(CSII)- regular insulin only
-
7/29/2019 Special Drug Delivery Systems
58/60
- can be programmed to deliver insulin at a low basal rate
( approx. 1 U/hr) and premeal boluses (4-15 times the basalrate to control post-prandial glycaemia.
- costly, risk of pump failure, site infection
Implantable insulin pumps: Consist of anelectromechanical mechanism which regulates insulindelivery from a percutaneously refillable reservoir.
- mechanical pumps, fluorocarbon propellant and osmotic
pumps are being developed
-
7/29/2019 Special Drug Delivery Systems
59/60
References: Essentials of medical pharmacology; KD Tripathi, 6th
edition Principles of pharmacology; HL Sharma, KK Sharma, 2ndedition Review of pharmacology; Gobind Rai Garg, Sparsh Gupta,
4th
edition Pharmacology and pharmacotherapeutics; RS Satoskar,SD Bhandarkar, Nirmala N Rege, 21st edition Goodman and Gilmans The pharmacological basis oftherapeutics; Brunton, Chabner, Knollman, 12th edition Basic and clinical pharmacology; Bertram G. Katzung,Susan B. Masters, Anthony J. Trevor, 11th edition
-
7/29/2019 Special Drug Delivery Systems
60/60
Thank You